GlassScriptPhysician profile
James A Gerardo
NPI 1306046438
$3,797.18
in general payments reported to CMS, 2019-2025
27 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $432 · 2021: $1,008 · 2022: $377 · 2023: $323 · 2024: $740 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,705.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,148.68 | 2019-2024 | Xarelto |
| Abbott Laboratories | $477.10 | 2021-2025 | Perclose Prostyle |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $336.09 | 2020-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $222.65 | 2022-2025 | |
| Amgen INC. | $186.61 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $168.44 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $153.78 | 2019-2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $137.38 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $136.75 | 2019-2023 | Brilinta, Farxiga |
| Kestra Medical Technology Services, INC. | $126.19 | 2023-2025 | Assure Wcd |
| Edwards Lifesciences Corporation | $120.85 | 2023 | Inspiris Resilia Aortic Valve |
| Medtronic, INC. | $94.00 | 2022-2024 | Onyx Frontier, Cobalt Dr Mri Surescan, Symplicity G3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.73 | 2024-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $65.73 | 2024-2025 | Uptravi, Opsumit |
| Abiomed | $60.63 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $42.17 | 2025 | |
| Sanofi-Aventis U.S. LLC | $32.32 | 2019 | |
| Teleflex LLC | $27.82 | 2025 | Guideliner |
| Atricure, INC. | $25.46 | 2022 | |
| Philips North America LLC | $25.07 | 2025 | Coronary Other |
| Boston Scientific Corporation | $24.92 | 2025 | Watchman Flx |
| Lantheus Medical Imaging, INC. | $24.41 | 2020-2023 | Definity |
| Novo Nordisk INC | $21.05 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $19.26 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $17.95 | 2020 | |
| Terumo Medical Corporation | $14.14 | 2022 | |
| Bardy Diagnostics, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gerardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.